Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2891364 | 0.90 | ADORA2A (0.49) | ADORA2AADORA3 | |
| SCHEMBL240014 | 0.89 | ADORA2A (0.48) | ADORA2AADORA3 | |
| SCHEMBL293209 | 0.88 | ADORA2A (0.54) | ADORA2AADORA3 | |
| SCHEMBL242804 | 0.88 | ADORA2A (0.54) | ADORA2AADORA3 | |
| SCHEMBL1831490 | 0.86 | ADORA2A (0.57) | ADORA2AADORA3 | |
| SCHEMBL2091877 | 0.86 | ADORA2A (0.56) | ADORA2AADORA3 | |
| SCHEMBL241197 | 0.86 | ADORA2A (0.56) | ADORA2AADORA3 | |
| SCHEMBL2091875 | 0.86 | ADORA2A (0.56) | ADORA2AADORA3 | |
| Hydrochloric Acid SCHEMBL241769 | 0.85 | ADORA2A (0.56) | ADORA2AADORA3 | |
| SCHEMBL240009 | 0.85 | ADORA2A (0.47) | ADORA2AADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2013211-B1 | PURINE DERIVATIVES FOR USE AS ADENOSIN A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2012-03-14 | — | — | EP | disclosed |
| US-20120004212-A1 | ORGANIC COMPOUNDS | NOVARTIS AG | 2012-01-05 | — | — | US | disclosed |
| US-20120004247-A1 | ORGANIC COMPOUNDS | NOVARTIS AG | 2012-01-05 | — | — | US | disclosed |
| EP-2322525-A1 | Purine derivatives for use as adenosin A2A receptor agonists | Novartis AG (CH) | 2011-05-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004212-A1 | ORGANIC COMPOUNDS | CYP3A43, SLCO1B3, CYP2C19 | ADORA2A 2741/4885ADORA3 795/4885 |
| US-20120004247-A1 | ORGANIC COMPOUNDS | CYP3A43, SLCO1B3, CYP2C19 | ADORA2A 2741/4885ADORA3 795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.